title: Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.
abstract: Marked parathyroid hyperplasia develops in patients with chronic kidney disease, especially those with long dialysis vintage. Although progression of hyperplasia is associated with downregulation of vitamin D receptor and calcium-sensing receptor, initial abnormality that triggers and maintains parathyroid cell proliferation, as well the critical abnormality for the progression of diffuse hyperplasia to nodular hyperplasia, still remains to be elucidated. It is quite important for the optimal management of renal osteodystrophy to recognize the development of nodular hyperplasia, because the cells in nodular hyperplasia are usually resistant to medical therapy and further treatment of such patients often leads to vascular calcification. For this purpose, size and blood supply of enlarged parathyroid glands have been used as good clinical markers. Furthermore, we have recently shown that the serum fibroblast growth factor 23 level can be used for predicting refractory hyperparathyroidism. Once nodular hyperplasia develops in any of the enlarged parathyroid glands, such patients need to be treated by parathyroid intervention including percutaneous ethanol injection therapy. In addition, as direct vitamin D injection therapy has been shown to induce regression of hyperplasia, it may become possible to reverse or normalize established nodular hyperplasia if we can develop new agents with such effects in the near future.
authors.affiliation: Division of Nephrology and Dialysis Center, Kobe University School of Medicine, Kobe, Japan. fukagawa@med.kobe-u-ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Fukagawa
authors.forename: S
authors.initials: S
authors.lastname: Nakanishi
authors.forename: J J
authors.initials: JJ
authors.lastname: Kazama
mesh_terms: D000891:Anti-Infective Agents, Local / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002114:Calcinosis / Q000097:blood* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D002908:Chronic Disease; D000431:Ethanol / Q000008:administration & dosage; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D006965:Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D007674:Kidney Diseases / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D010280:Parathyroid Glands / Q000378:metabolism* / Q000473:pathology*; D018167:Receptors, Calcitriol / Q000378:metabolism; D044169:Receptors, Calcium-Sensing / Q000378:metabolism; D014807:Vitamin D / Q000008:administration & dosage
chemical_list: D000891:Anti-Infective Agents, Local; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D018167:Receptors, Calcitriol; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D000431:Ethanol; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23